We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$474M
AUM Growth
+$427M
Cap. Flow
+$433M
Cap. Flow %
91.18%
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$6.86M
2
BBDC icon
Barings BDC
BBDC
+$6.33M
3
OXSQ icon
Oxford Square Capital
OXSQ
+$5.45M
4
ECC
Eagle Point Credit Company
ECC
+$5.29M
5
FSK icon
FS KKR Capital
FSK
+$5.24M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$2.25M
2
ACOR
Acorda Therapeutics
ACOR
+$644K
3
ARRY
Array Biopharma Inc
ARRY
+$605K
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$603K
5
QURE icon
uniQure
QURE
+$374K

Sector Composition

Rank Sector Weight
1 Financials 23.58%
2 Real Estate 14.99%
3 Energy 13.55%
4 Healthcare 12.23%
5 Materials 8.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
251
DELISTED
Blueprint Medicines
BPMC
$278K 0.06%
2,951
-1,790
-38% -$148K
AIMT
252
DELISTED
Aimmune Therapeutics
AIMT
$278K 0.06%
13,338
+1,345
+11% +$27.7K
ITCI
253
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$277K 0.06%
21,322
+2,444
+13% +$31.3K
ALLK
254
DELISTED
Allakos
ALLK
$275K 0.06%
6,338
+1,901
+43% +$78K
AKCA
255
DELISTED
Akcea Therapeutics Inc
AKCA
$275K 0.06%
11,730
+3,203
+38% +$79.1K
ARWR icon
256
Arrowhead Research
ARWR
$12.1B
$274K 0.06%
10,330
-7,790
-43% -$171K
DNTH icon
257
Dianthus Therapeutics
DNTH
$5.68B
$274K 0.06%
+1,161
New +$287K
ALLO icon
258
Allogene Therapeutics
ALLO
$601M
$271K 0.06%
+10,084
New +$281K
WVE icon
259
Wave Life Sciences
WVE
$1.12B
$271K 0.06%
10,387
+5,014
+93% +$141K
CRBP icon
260
Corbus Pharmaceuticals
CRBP
$170M
$270K 0.06%
1,298
-56
-4% -$12K
FTSV
261
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$268K 0.06%
+25,314
New +$372K
BOLD
262
DELISTED
Audentes Therapeutics, Inc
BOLD
$267K 0.06%
7,053
-4,663
-40% -$179K
EIDX
263
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$264K 0.06%
8,495
-9,109
-52% -$247K
RYTM icon
264
Rhythm Pharmaceuticals
RYTM
$7B
$263K 0.06%
11,938
+2,470
+26% +$62.4K
ALDR
265
DELISTED
Alder Biopharmaceuticals
ALDR
$261K 0.06%
+22,154
New +$268K
GBT
266
DELISTED
Global Blood Therapeutics, Inc.
GBT
$260K 0.05%
4,938
-1,404
-22% -$80.7K
ORTX
267
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$256K 0.05%
+1,833
New +$322K
PRNB
268
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$256K 0.05%
7,700
-1,348
-15% -$42.1K
ACHN
269
DELISTED
Achillion Pharmaceuticals
ACHN
$256K 0.05%
95,598
+8,694
+10% +$25.7K
ASND icon
270
Ascendis Pharma A/S
ASND
$16.7B
$255K 0.05%
2,214
-2,036
-48% -$244K
LJPC
271
DELISTED
La Jolla Pharmaceutical Company
LJPC
$254K 0.05%
+27,470
New +$207K
ESPR
272
DELISTED
Esperion Therapeutics
ESPR
$253K 0.05%
5,430
-53
-1% -$2.49K
MRNA icon
273
Moderna
MRNA
$21.5B
$253K 0.05%
+17,311
New +$372K
GERN icon
274
Geron
GERN
$911M
$252K 0.05%
+179,012
New +$296K
ALEC icon
275
Alector
ALEC
$164M
$251K 0.05%
+13,224
New +$268K
9 10
11
12 13

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2019 Portfolio in Review

As of Q2 2019, Virtus ETF Advisers held 454 positions worth $474M, up 909% from $47M the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Virtus ETF Advisers deployed $433M of net new capital in Q2 2019, opening 296 new positions and adding to 64 existing holdings. Its largest new stake was Oxford Lane Capital: 132,284 shares worth $6.67M.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 0.73% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $605K trimmed.

  • Virtus ETF Advisers's largest Q2 2019 buy was Oxford Lane Capital: 132,284 shares worth $6.67M.
  • Virtus ETF Advisers added most to Dominion Energy in Q2 2019, an estimated $2.63M increase.
  • Virtus ETF Advisers's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $605K.
  • Virtus ETF Advisers fully exited Spark Therapeutics, Inc. Common Stock in Q2 2019, selling an estimated $2.25M.
  • Virtus ETF Advisers's ten largest holdings make up 11% of its $474M portfolio in Q2 2019.
  • Virtus ETF Advisers opened 296 new positions and closed 20 in Q2 2019.
  • Virtus ETF Advisers's portfolio value rose 909% quarter-over-quarter to $474M.

Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.